Icon Plc (ICLR) Given Consensus Recommendation of “Buy” by Brokerages
Shares of Icon Plc (NASDAQ:ICLR) have earned an average recommendation of “Buy” from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $123.80.
A number of brokerages have recently issued reports on ICLR. KeyCorp reaffirmed a “buy” rating and set a $130.00 price target on shares of Icon in a report on Thursday, January 11th. Zacks Investment Research cut shares of Icon from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Mizuho set a $109.00 price objective on shares of Icon and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Barclays increased their price objective on shares of Icon from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Friday, October 27th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $123.00 price objective on shares of Icon in a research note on Thursday, October 12th.
Several large investors have recently modified their holdings of the company. Chartwell Investment Partners LLC lifted its stake in shares of Icon by 36.2% in the 4th quarter. Chartwell Investment Partners LLC now owns 40,548 shares of the medical research company’s stock worth $4,547,000 after purchasing an additional 10,770 shares during the period. Wells Fargo & Company MN lifted its stake in shares of Icon by 2.5% in the 4th quarter. Wells Fargo & Company MN now owns 1,078,196 shares of the medical research company’s stock worth $120,920,000 after purchasing an additional 26,361 shares during the period. First Trust Advisors LP bought a new position in shares of Icon in the 4th quarter worth approximately $593,000. Private Advisor Group LLC bought a new position in shares of Icon in the 4th quarter worth approximately $216,000. Finally, Sentry Investment Management LLC lifted its stake in shares of Icon by 2.1% in the 4th quarter. Sentry Investment Management LLC now owns 37,807 shares of the medical research company’s stock worth $4,240,000 after purchasing an additional 763 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2018/02/08/icon-plc-iclr-given-consensus-recommendation-of-buy-by-brokerages.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.